Detection of multiple activating NRAS variants under BRAF/MEK-inhibitor therapy in BRAF positive malignant melanoma using liquid biopsy

This is the authors' abstract. We don't add key points for this paper.

Malignant melanoma is one of the most common skin cancers worldwide.1 The most frequent driver mutation is BRAF V600E, observed in about 50% of patients and a target for kinase inhibitor therapy.2 In addition, activating mutations in NRAS are found in up to 20% of melanomas,2 showing a more aggressive presentation and a poorer prognosis.3 Monitoring of therapy response by radiography or clinical parameters is poorly correlated with patient survival.4 In recent years, liquid biopsy (LB) is increasingly used to monitor therapy responses in patients with cancer.